EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development and validation of next-generation sequencing panel for personalized Helicobacter pylori eradication treatment targeting multiple species

Byung-Joo Min, Myung-Eui Seo, Jung Ho Bae, Ji Won Kim, Ju Han Kim

Frontiers in Cellular and Infection Microbiology · 2024

DOI: 10.3389/fcimb.2024.1379790 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2024. Verfasst von Byung-Joo Min und 4 weiteren Autor:innen. Beteiligte Einrichtung: Forensic DNA Division, National Forensic Service Seoul Institute, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Helicobacter pylori, Helicobacter Infections, High-Throughput Nucleotide Sequencing, Anti-Bacterial Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The decreasing Helicobacter pylori eradication rate is primarily attributed to antibiotic resistance, and further exacerbated by uniform drug administration disregarding a host’s metabolic capability. Consequently, applying personalized treatment based on antibiotic resistance-associated variants and the host’s metabolic phenotype can potentially increase the eradication rate.

Method

A custom next-generation sequencing panel for personalized H. pylori eradication treatment (NGS-PHET) was designed which targeted the regions for amoxicillin, clarithromycin, metronidazole, tetracycline, and levofloxacin-resistance in H. pylori and human proton-pump inhibitor (PPI) metabolism. The libraries were constructed following customized methods and sequenced simultaneously. The customized framework criteria, grounded in previously reported antibiotic resistance associated variants and the host’s PPI metabolism, was applied to the NGS-PHET results and suggested a personalized treatment for each subject, which was validated through each subject’s actual eradication outcome.

Results

Both previously reported and novel variants were identified from H. pylori sequencing results. Concurrently, five CYP2C19 homozygous extensive metabolizers and three CYP3A4 intermediate metabolizers were identified. Among the total of 12 subjects, clarithromycin triple therapy was suggested for five subjects, bismuth quadruple therapy was suggested for six subjects, and rifabutin triple therapy was suggested for one subject by following the customized framework criteria. The treatment suggestion for nine of the 12 subjects was consistent with the treatment that each subject achieved eradication with.

Discussion

Applying the methodology using the NGS-PHET and customized framework helps to perform eradication treatment quickly and effectively in most patients with antibiotic-resistant H. pylori strains, and is also useful in research to find novel antibiotic-resistance candidates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter pyloriHelicobacter InfectionsHigh-Throughput Nucleotide SequencingAnti-Bacterial AgentsPrecision MedicineHumansProton Pump InhibitorsClarithromycinMaleDrug Resistance, BacterialMiddle AgedFemaleAdultDrug Therapy, CombinationMetronidazoleAmoxicillinCytochrome P-450 CYP2C19Microbial Sensitivity TestsLevofloxacinTetracyclineTreatment Outcome

Stichwörter der Autor:innen

antibiotic resistanceindividual antibiotic resistance profilemultispecies integrated next-generation sequencing panelpersonalized Helicobacter pylori eradication treatmentproton-pump inhibitor metabolic phenotype

Substanzen

Anti-Bacterial AgentsProton Pump InhibitorsClarithromycinMetronidazoleAmoxicillinCytochrome P-450 CYP2C19LevofloxacinTetracycline

Autor:innen und Institutionen

  • Forensic DNA Division, National Forensic Service Seoul Institute, Seoul, Republic of Korea.
  • Seoul National University Biomedical Informatics (SNUBI), Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Department of Internal Medicine and Healthcare Research Institute, Healthcare System Gangnam Center, Seoul National University Hospital, Seoul, Republic of Korea.
  • Department of Internal Medicine, Seoul Metropolitan Government - Seoul National University Boramae Medical Center, Seoul, Republic of Korea.
  • Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Seoul National University Biomedical Informatics (SNUBI), Division of Biomedical Informatics, Seoul National University College of Medicine, Seoul, Republic of Korea.

Zitieren

APA

Min, B. J., Seo, M. E., Bae, J. H., Kim, J. W., & Kim, J. H. (2024). Development and validation of next-generation sequencing panel for personalized Helicobacter pylori eradication treatment targeting multiple species. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2024.1379790

Vancouver

Min BJ, Seo ME, Bae JH, Kim JW, Kim JH. Development and validation of next-generation sequencing panel for personalized Helicobacter pylori eradication treatment targeting multiple species. Frontiers in Cellular and Infection Microbiology. 2024. doi:10.3389/fcimb.2024.1379790

BibTeX
@article{Min2024,
  author = {Min, Byung-Joo and Seo, Myung-Eui and Bae, Jung Ho and Kim, Ji Won and Kim, Ju Han},
  title = {Development and validation of next-generation sequencing panel for personalized Helicobacter pylori eradication treatment targeting multiple species},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2024},
  doi = {10.3389/fcimb.2024.1379790}
}
Kostenlos starten →